Literature DB >> 9398449

Effects of isradipine, an L-type calcium channel blocker on permanent and transient focal cerebral ischemia in spontaneously hypertensive rats.

C A Campbell1, K B Mackay, S Patel, P D King, J L Stretton, S J Hadingham, T C Hamilton.   

Abstract

Permanent or transient focal cerebral ischemia was induced in spontaneously hypertensive rats (SHR) using the intraluminal filament method. Successful occlusion of the middle cerebral artery (MCA) was achieved using 4/O filaments (terminal diameter 0.20-0.25 mm) coated with poly-L-lysine. The L-type calcium channel blocker isradipine (2.5 mg/kg) administered subcutaneously 30 min following permanent MCA occlusion significantly reduced the volume of ischemic brain damage in the cerebral hemisphere (25%; P = 0.0001), cerebral cortex (18%; P = 0.0034), and caudate nucleus (33%; P = 0.0002) when assessed at 24 h post-MCA occlusion. Isradipine did not affect the functional deficit (measured using a subjective neurological scoring system) induced by MCA occlusion. In SHR undergoing transient (2 h) MCA occlusion isradipine administered 30 min post-MCA occlusion produced a significant reduction (47%; P = 0.001) in hemispheric infarct volume, whereas isradipine administered at the onset of reperfusion did not confer any significant neuroprotection. No change in functional deficit was seen with isradipine with either dosing paradigm at 24 h post-MCA occlusion. These results demonstrate that the intraluminal filament method of MCA occlusion can be used in the SHR strain and also substantiates the neuroprotective efficacy of isradipine in SHR models of permanent and transient focal cerebral ischemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9398449     DOI: 10.1006/exnr.1997.6611

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  8 in total

Review 1.  Calcium channel blocking as a therapeutic strategy for Alzheimer's disease: the case for isradipine.

Authors:  Thimmappa S Anekonda; Joseph F Quinn
Journal:  Biochim Biophys Acta       Date:  2011-09-08

Review 2.  Ammonia, like K(+), stimulates the Na(+), K(+), 2 Cl(-) cotransporter NKCC1 and the Na(+),K(+)-ATPase and interacts with endogenous ouabain in astrocytes.

Authors:  Leif Hertz; Liang Peng; Dan Song
Journal:  Neurochem Res       Date:  2014-06-15       Impact factor: 3.996

3.  Calcium antagonist isradipine reduces metabolic alterations in acute cerebral ischemia in spontaneously hypertensive rats.

Authors:  S Ibayashi; T Nagao; T Kitazono; H Ooboshi; J Kitayama; S Sadoshima; M Fujishima
Journal:  Neurochem Res       Date:  2000-03       Impact factor: 3.996

Review 4.  The mechanisms of brain ischemic insult and potential protective interventions.

Authors:  Zhao-Hui Guo; Feng Li; Wei-Zhi Wang
Journal:  Neurosci Bull       Date:  2009-06       Impact factor: 5.203

Review 5.  Control of intracellular calcium signaling as a neuroprotective strategy.

Authors:  R Scott Duncan; Daryl L Goad; Michael A Grillo; Simon Kaja; Andrew J Payne; Peter Koulen
Journal:  Molecules       Date:  2010-03-03       Impact factor: 4.411

6.  Antagonists of the Vasopressin V1 Receptor and of the β(1)-Adrenoceptor Inhibit Cytotoxic Brain Edema in Stroke by Effects on Astrocytes - but the Mechanisms Differ.

Authors:  Leif Hertz; Junnan Xu; Ye Chen; Marie E Gibbs; Ting Du; Leif Hertz; Junnan Xu; Ye Chen; Marie E Gibbs; Ting Du
Journal:  Curr Neuropharmacol       Date:  2014-07       Impact factor: 7.363

7.  A molecular approach to treating cognition in schizophrenia by calcium channel blockade: An open-label pilot study of the calcium-channel antagonist isradipine.

Authors:  Katherine E Burdick; Mercedes Perez-Rodriguez; Rebecca Birnbaum; Megan Shanahan; Emmett Larsen; Cierra Harper; Jessica Poskus; Pamela Sklar
Journal:  Schizophr Res Cogn       Date:  2020-05-18

8.  Ionic Mechanism Underlying Rebound Depolarization in Medial Prefrontal Cortex Pyramidal Neurons.

Authors:  Przemysław Kurowski; Katarzyna Grzelka; Paweł Szulczyk
Journal:  Front Cell Neurosci       Date:  2018-04-23       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.